Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Regular Injection Clear all
Terminated Not applicable Interventional

Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

NCT00250081
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Tendon transfer, Botulinum Toxin injections in Upper Extremity, Regularly ongoing therapy
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 21, 2026, 2:22 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 21, 2026, 2:22 PM EDT
Withdrawn Phase 2 Interventional

Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting

NCT01765738
View directory record Official record
Conditions
Peripherally Inserted Central Catheters
Interventions
PICC (Cook, Bard)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

NCT00858273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant supplement, Diabetes treatment, Regular Insulin
Dietary Supplement · Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

NCT04681729
View directory record Official record
Conditions
Cold Urticaria
Interventions
Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 21, 2026, 2:22 PM EDT
Completed No phase listed Observational

Impact of Exenatide on Sleep Duration

NCT01416649
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

NCT00862849
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Regular Human Insulin, rHuPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 21, 2026, 2:22 PM EDT
Withdrawn Phase 3 Interventional

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395
View directory record Official record
Conditions
Fever of Unknown Origin
Interventions
68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT
Drug · Device
Lead sponsor
Carina Mari Aparici
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 2Phase 3 Interventional

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT03974113
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allergy Immunotherapy for the Reduction of Asthma

NCT01028560
View directory record Official record
Conditions
Wheezing, Asthma, Allergy
Interventions
Allergen extracts (subcutaneous injections), Standard of care
Biological · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Months to 3 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Patient Experience Study of Deoxycholic Acid Injection

NCT02007434
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
Drug · Other
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 21, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Amnioinfusion for Fetal Renal Failure

NCT06728228
View directory record Official record
Conditions
Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Bilateral Renal Agenesis
Interventions
Amnioinfusion
Other
Lead sponsor
Fetal Care Center, PLLC
Industry
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 21, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

NCT04904757
View directory record Official record
Conditions
Mammographic Breast Density, Mammography
Interventions
Contrast-enhanced spectral mammography (CESM)
Device
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Positive Piggy Bank - A Positive Activities Intervention for Improving Functional Status in Patients With Back Pain

NCT02476812
View directory record Official record
Conditions
Low Back Pain
Interventions
Positive Piggy Bank
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 2:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Microdosing ICG for Serial Colonic Perfusion Study During Surgery

NCT06254833
View directory record Official record
Conditions
Perfusion; Complications
Interventions
micro dosing of ICG
Other
Lead sponsor
Shanglei Liu
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

NCT02561078
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Mobile, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 21, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 21, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 21, 2026, 2:22 PM EDT